Olivier Micheau spends much of his time researching Cell biology, Apoptosis, Death domain, Fas receptor and FADD. His Cell biology research includes elements of TRADD, Death-inducing signaling complex, Ripoptosome and Caspase 8. His Caspase 8 study integrates concerns from other disciplines, such as RIPK1 and Necroptosis.
The Apoptosis study combines topics in areas such as Tumor necrosis factor alpha, Molecular biology, Cancer research and Receptor. His work in Molecular biology addresses subjects such as DNA fragmentation, which are connected to disciplines such as Caspase. He interconnects Kinase and Receptor complex in the investigation of issues within Signal transducing adaptor protein.
His primary scientific interests are in Apoptosis, Cell biology, Cancer research, Programmed cell death and Cancer cell. His Apoptosis study combines topics from a wide range of disciplines, such as Tumor necrosis factor alpha, Receptor, Cytotoxic T cell and Molecular biology. His work carried out in the field of Cell biology brings together such families of science as Fas receptor, Death domain, Caspase 8 and Fas ligand.
The Death domain study which covers FADD that intersects with Signal transducing adaptor protein. His Cancer research research is multidisciplinary, relying on both Carcinogenesis, Cancer, Immunology, Immune system and In vivo. His research on Programmed cell death also deals with topics like
Olivier Micheau mainly investigates Apoptosis, Cancer research, Receptor, Tumor necrosis factor alpha and Cell biology. His study on FADD is often connected to Magnetic hyperthermia as part of broader study in Apoptosis. The study incorporates disciplines such as Cancer cell, Cancer and Programmed cell death in addition to Cancer research.
His work in the fields of Receptor, such as Agonist and HEK 293 cells, intersects with other areas such as Molecular dynamics and Affinity chromatography. His study in Tumor necrosis factor alpha is interdisciplinary in nature, drawing from both Cell culture, Transferrin, Cytokine, Malignant cells and Immune system. Particularly relevant to Signal transduction is his body of work in Cell biology.
Olivier Micheau mainly focuses on Receptor, Cancer research, Agonist, Cell biology and Apoptosis. His studies in Cancer research integrate themes in fields like Cancer cell, Cancer, Kinase and Programmed cell death. His work on Dependence receptor as part of general Programmed cell death study is frequently linked to Ectodysplasin A receptor, bridging the gap between disciplines.
His research in Agonist tackles topics such as Tumor necrosis factor alpha which are related to areas like Antibody and Cytokine. His research in Cell biology intersects with topics in Trail r1, Glycosylation, FADD and Ligand. His research integrates issues of Molecular biology and Calcium flux in his study of Apoptosis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Induction of TNF Receptor I-Mediated Apoptosis via Two Sequential Signaling Complexes
Olivier Micheau;Jürg Tschopp.
Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule.
Nils Holler;Rossana Zaru;Olivier Micheau;Margot Thome.
Nature Immunology (2000)
NF-κB Signals Induce the Expression of c-FLIP
Olivier Micheau;Susanne Lens;Olivier Gaide;Kostis Alevizopoulos.
Molecular and Cellular Biology (2001)
The Long Form of FLIP Is an Activator of Caspase-8 at the Fas Death-inducing Signaling Complex
Olivier Micheau;Margot Thome;Pascal Schneider;Nils Holler.
Journal of Biological Chemistry (2002)
Recruitment of TNF Receptor 1 to Lipid Rafts Is Essential for TNFα-Mediated NF-κB Activation
Daniel F Legler;Daniel F Legler;Olivier Micheau;Marie-Agnès Doucey;Jürg Tschopp.
Fas Ligand-independent, FADD-mediated Activation of the Fas Death Pathway by Anticancer Drugs
Olivier Micheau;Eric Solary;Arlette Hammann;Marie-Thérèse Dimanche-Boitrel.
Journal of Biological Chemistry (1999)
Sensitization of Cancer Cells Treated With Cytotoxic Drugs to Fas-Mediated Cytotoxicity
Olivier Micheau;Eric Solary;Arlette Hammann;François Martin.
Journal of the National Cancer Institute (1997)
Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2
Delphine Mérino;Najoua Lalaoui;Alexandre Morizot;Pascal Schneider.
Molecular and Cellular Biology (2006)
Carma1, a CARD‐containing binding partner of Bcl10, induces Bcl10 phosphorylation and NF‐κB activation1
Olivier Gaide;Fabio Martinon;Olivier Micheau;David Bonnet.
FEBS Letters (2001)
Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells.
Dominique Delmas;Cédric Rébé;Olivier Micheau;Anne Athias.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: